Condition
Non Small Cell Lung Cancer Recurrent
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 6 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
6 shownToripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)NCT05842018 · 2023-05-01
UNKNOWNA Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 ExpressionNCT05736731 · 2023-04-28
ACTIVE_NOT_RECRUITINGPharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male SubjectsNCT05110118 · 2020-08-04
COMPLETEDA Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung CancerNCT03533127 · 2017-11-27
UNKNOWNCancer Panel From Blood of Lung Cancer PatientsNCT03235765 · 2017-03-10
UNKNOWNA Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung CancerNCT02967133 · 2016-12-01
TERMINATEDCommon interventions
Leading sponsors
Trial status mix
UNKNOWN3
ACTIVE_NOT_RECRUITING1
COMPLETED1
TERMINATED1
Phase mix
PHASE23
PHASE12
PHASE31
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.